Evidence map›Paper›PMID 32158555›Full record

ArticleSouthern African journal of HIV medicine2020

Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy.

Globahan Ajibola, Christopher Rowley, Dorcas Maruapula, Jean Leidner, Kara Bennett, Kathleen Powis, Roger L Shapiro, Shahin Lockman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Southern African journal of HIV medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Globahan AjibolaBotswana Harvard T.H. Chan School of Public Health AIDS Initiative Partnership, Gaborone, Botswana.ORCID https://orcid.org/0000-0002-5408-4823
Christopher RowleyBotswana Harvard T.H. Chan School of Public Health AIDS Initiative Partnership, Gaborone, Botswana.ORCID https://orcid.org/0000-0001-9211-8476
Dorcas MaruapulaBotswana Harvard T.H. Chan School of Public Health AIDS Initiative Partnership, Gaborone, Botswana.ORCID https://orcid.org/0000-0003-2587-8904
Jean LeidnerGoodtables Data Consulting, LLC., Norman, United States.ORCID https://orcid.org/0000-0002-4707-3747
Kara BennettBennett Statistical Consulting, Inc., Ballston Lake, United States.ORCID https://orcid.org/0000-0002-9465-8983
Kathleen PowisBotswana Harvard T.H. Chan School of Public Health AIDS Initiative Partnership, Gaborone, Botswana.ORCID https://orcid.org/0000-0002-4478-4471
Roger L ShapiroBotswana Harvard T.H. Chan School of Public Health AIDS Initiative Partnership, Gaborone, Botswana.ORCID https://orcid.org/0000-0002-4832-6275
Shahin LockmanBotswana Harvard T.H. Chan School of Public Health AIDS Initiative Partnership, Gaborone, Botswana.ORCID https://orcid.org/0000-0002-5384-9716
Botswana Harvard AIDS Institute Partnership · BWHadassah Medical Center · ILHarvard University · US

Funding

Short Breastfeeding and Cotrimoxazole among HIV-Exposed Infants in BotswanaR01HD061265 · NICHD · HARVARD SCHOOL OF PUBLIC HEALTH · PI LOCKMAN, SHAHIN, SHAPIRO, ROGER L · 2010 to 2015
$4.5M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
Expansion of research and mentoring to improve birth outcomes and treatment outcomes among HIV-affected children in BotswanaK24AI131924 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Roger L Shapiro · 2018 to 2026
$1.6M
FIC NIH HHS D43 TW009610NIAID NIH HHS K24 AI131924NIAID NIH HHS K24 AI131928NICHD NIH HHS R01 HD061265
6 · The paper itself

Abstract

backgroundTo reduce risk of antiretroviral resistance when stopping efavirenz (EFV)-based antiretroviral treatment (ART), staggered discontinuation of antiretrovirals (an NRTI tail) is recommended. However, no data directly support this recommendation.

objectivesWe evaluated the prevalence of HIV drug resistance mutations in pregnant women living with HIV who stopped efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) postpartum.

methodIn accordance with the prevailing Botswana HIV guidelines at the time, women with pre-treatment CD4 > 350 cells/mm

resultsFrom April 2014 to May 2015, 74 women who had stopped EFV/FTC/TDF enrolled, with median nadir CD4 of 571 cells/mm

conclusionsViral rebound was slow following cessation of EFV/FTC/TDF in the postpartum period. Use of an FTC/TDF tail after stopping EFV was associated with the lower prevalence of subsequent NNRTI drug resistance mutation.

Indexed as

antiretroviral treatmentBotswanadrug resistanceHIVresistance mutations

Identifiers

PMID32158555
PMCPMC7059240
OpenAlexW3003009889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.